WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

Acquisition

Medtronic closes $650M purchase of SPR Therapeutics

MedDevice Startups Staff · Jul 17 · 2 min read · Via MedTech Dive (closing)

Medtronic completed its acquisition of SPR Therapeutics on July 17, 2026, paying $650 million in cash for all outstanding equity. The deal was announced on May 20.

SPR makes Sprint, a peripheral nerve stimulation system for acute and chronic pain that uses a temporary lead placed for up to 60 days rather than a permanent implant. FDA cleared it through the 510(k) pathway, the company passed 50,000 implants by the end of 2025, and pooled results from 13 studies show 60 percent of patients reaching at least a 50 percent reduction in pain at the end of the 60-day treatment.

Domenico De Paolis, Medtronic's interim president of neuromodulation, said at announcement that a temporary peripheral nerve stimulation option would let physicians intervene earlier. It is the third acquisition Medtronic has announced in 2026, after CathWorks for $585 million and Scientia Vascular for $550 million, and its CFO has called neuromodulation a growth area expanding at more than 20 percent a year.

Questions & Answers

How much did Medtronic pay for SPR Therapeutics?

$650 million in cash for all outstanding equity. Medtronic announced the deal on May 20, 2026 and closed it on July 17, 2026.

What is SPR Therapeutics' Sprint system?

Sprint is a peripheral nerve stimulation system for acute and chronic pain. A temporary lead is placed for up to 60 days instead of a permanent implant. It is FDA cleared and passed 50,000 implants by the end of 2025.

What other deals has Medtronic done in 2026?

Before SPR Therapeutics, Medtronic bought CathWorks for $585 million, closed in April 2026, and announced the $550 million purchase of Scientia Vascular in March 2026.

← Back to M&A